MedPath

Study of Microwave Spherical Ablation and Traditional Microwave Ablation in Single Hepatocellular Carcinoma ≤5cm

Not Applicable
Recruiting
Conditions
Microwave Ablation
Microwave Spherical Ablation
Prognosis
Hepatocellular Cancer
Interventions
Device: True circular microwave needle
Registration Number
NCT05361538
Lead Sponsor
Tianjin Third Central Hospital
Brief Summary

Comparison of the progression-free survival, overall survival, local progression rates, complete ablation rates and the complications rate of MSA and traditional MWA in the treatment of single hepatocellular carcinoma with a diameter of ≤5cm.

Detailed Description

HCC is a serious threat to the health of people,Early treatment of HCC results in a good prognosis for patients. Microwave ablation (MWA) is an important method for the treatment of early HCC. The traditional MWA technology has a long diameter of the ablation foci which is much larger than the transverse diameter, so in order to obtain a sufficient transverse diameter, the long diameter is often too large beyond the tumor boundary. That will cause too much normal liver tissue is unnecessarily damaged, especially for patients with severe liver cirrhosis or patients with liver cirrhosis who have undergone liver resection. In addition, it is easy to cause damage to adjacent vital tissues and organs. Changes in tissue properties during ablation affect the stability of the microwave field, resulting in unpredictable ablation shapes, which may cause omissions during tumor ablation, especially in multiple overlapping ablation, resulting in incomplete ablation, or increasing the risk of local tumor progression after treatment. Microwave spherical ablation (MSA) technology is a new MWA technology. With the help of temperature control technology, field control technology and wave control technology, a single needle can produce predictable spherical ablation lesions. Theoretically, MSA can improve the controllability of the ablation foci, which is suitable for the purpose of conformal ablation of large tumors in clinical practice, thereby minimizing the damage of local thermal ablation to liver tissue and adjacent important organs. However, there are few reports on the comparison of the therapeutic effect of MSA and traditional MWA. This study intends to conduct a prospective randomized controlled study based on the two mature microwave treatment methods of MSA and traditional MWA ablation to explore the effectiveness and safety of MSA in clinical application, providing evidence-based medical evidence for the clinical application of MSA.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
60
Inclusion Criteria
  1. Patient has high risk factors for HCC and was first diagnosed of HCC by by contrast-enhanced imaging (CECT/CEMRI/CEUS) and/or pathology ;
  2. Age range 18 to 75 years old;
  3. Single lesion with tumor diameter ≤5cm;
  4. Patient refuses surgery and determines to undergo microwave ablation
  5. Liver function Child Pugh A or B;
  6. No extrahepatic metastasis or portal invasion;
  7. Patient signs the informed consent.
Exclusion Criteria
  1. The lesion has received treatment, including local ablation therapy and TACE therapy, etc;
  2. With portal vein invasion or extrahepatic metastases;
  3. Patient is with severe cardiopulmonary insufficiency.
  4. Patient is a pregnant or breastfeeding women.
  5. Patient is considered to be unsuitable to participate in the study

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
MTA GroupTrue circular microwave needleUse true circular microwave needle for ultrasound-guided thermal ablation in MSA (microwave spherical ablation) group.
Primary Outcome Measures
NameTimeMethod
Comparison of progression-free survival between MSA and traditional MWA in HCC6 to 12 months

Compare the time to tumor progression after therapy of MSA and traditional MWA in the treatment of single hepatocellular carcinoma with a diameter of ≤5 cm

Secondary Outcome Measures
NameTimeMethod
Comparison of the overall survival of MSA and traditional MWA in HCC12 to 60 months

Compare the time to of all-cause mortality after therapy of MSA and traditional MWA in the treatment of single hepatocellular carcinoma with a diameter of ≤5cm

Comparison of complete ablation rates of MSA and traditional MWA in HCC1 month

Complete ablation was defined as the tumor showing no enhancement in three stages on contrast-enhanced imaging. Compare the rate of complete ablation after therapy of MTA and traditional MWA in the treatment of single hepatocellular carcinoma with a diameter of ≤5 cm

Comparison of the complications rate of MSA and traditional MWA in HCCimmediately

Compare the rate of the complications during and after the therapy of MSA and traditional MWA in the treatment of patients with single hepatocellular carcinoma with a diameter of ≤5cm

Comparison of local progression rates of MSA and traditional MWA in HCC6 to 12 months

Local progression was defined as new lesions with hyperenhancement in the arterial phase and low enhancement in the portal or delayed phase found adjacent to the ablation lesion (≤5 mm) during follow-up. Compare the local progression rates after therapy of MTA and traditional MWA in the treatment of single hepatocellular carcinoma with a diameter of ≤ 5 cm

Trial Locations

Locations (1)

Tianjin Third Central Hospital

🇨🇳

Tianjin, Tianjin, China

© Copyright 2025. All Rights Reserved by MedPath